# Lantheus Holdings

Type: Company (LNTH)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/lantheus-holdings
Canonical HTML page: https://getbiobrief.com/entity/lantheus-holdings

## Recent coverage (2 stories)

### Lantheus and Heron Post Mixed Q4 Results as FY26 Guidance Takes Center Stage
2026-02-26 13:15:34 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter financial results, highlighting a period of transition for the mid-cap biotech sector. While both companies provided initial FY26 outlooks, market attention is shifting toward their respective commercial scaling efforts and pipeline execution.
Full story: https://getbiobrief.com/story/lantheus-heron-q4-earnings-fy26-outlook

### Q4 2025 Biotech Earnings: Delcath and Peers Face Critical Commercial Milestones
2026-02-25 15:07:22 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings season commences, Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings are under intense scrutiny regarding their commercial execution and path to profitability. Investors are particularly focused on Delcath's HEPZATO KIT rollout and Lantheus's ability to maintain its dominance in the competitive radiopharmaceutical market.
Full story: https://getbiobrief.com/story/biotech-pharma-q4-2025-earnings-preview-delcath-lantheus

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.